Skip to main content
Premium Trial:

Request an Annual Quote

Enzo, Yale Sue Applera for Infringing Sequencing Reagent Patents

NEW YORK, June 8 (GenomeWeb News) - Enzo Biochem today said that it has filed suit against Applera for infringing patented technologies related to DNA sequencing systems.


The suit, filed in the US District Court for the District of Connecticut against Applera and its Tropix subsidiary, charges the firms with infringing US Patent Nos. 5,476,928; 5,449,767; 5,328,824; 4,711,955; 5,082,830; and 4,994,373. Four of these patents are exclusively licensed to Enzo by YaleUniversity, which is also a named as a plaintiff in the suit. The remaining patents are owned by Enzo Biochem's subsidiary, Enzo Life Sciences.


The patent suite covers compounds used in DNA sequencing systems. In a statement, Enzo said that Applera and Tropix "improperly make, use and sell the patented products and technologies, as well as providing others with unauthorized and prohibited access to the patented products and technologies."


Enzo and Yale are seeking "injunctive relief and monetary damages."


The Scan

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.

Tibetan Study Finds Adaptive Variant Influencing Skin Pigmentation

With a combination of phenotyping and genetic data, researchers document at PNAS a Tibetan-enriched enhancer variant influencing melanin synthesis and ultraviolet light response.

Domestication Linked to Nervous System Genes in Inbred Mouse Strains

Researchers highlighted more than 300 positively selected genes in domesticated mice, including genes linked to nervous system function or behavior in Genome Biology.

ALS Genetic Testing May Be Informative Across Age Ranges, Study Finds

Researchers in the journal Brain identified clinically actionable variants in a significant subset of older ALS patients, prompting them to point to the potential benefits of broader test use.